Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan;45(1):e16211.
doi: 10.1111/liv.16211.

PNPLA3 in Alcohol-Related Liver Disease

Clélia Galvanin  1   2 , Stephan Buch  3   4 , Pierre Nahon  5   6   7 , Eric Trépo  1   2
Affiliations
Review

PNPLA3 in Alcohol-Related Liver Disease

Clélia Galvanin et al. Liver Int. 2025 Jan.

Abstract

The discovery of PNPLA3 as a genetic risk factor for liver disease has transformed our understanding of the pathogenesis of alcohol-related liver disease (ALD). The recent reclassification of fatty liver disease as steatotic liver disease (SLD), introducing metabolic dysfunction and alcohol-related liver disease (MetALD), has highlighted how genetic and environmental factors synergistically drive liver damage. The PNPLA3 rs738409 variant stands as a paradigmatic example of gene-environment interaction, where its effect on liver disease is dramatically amplified by alcohol consumption, obesity and type 2 diabetes. Understanding these interactions has revealed novel pathogenic mechanisms. The robust genetic evidence and a growing understanding of molecular mechanisms have made PNPLA3 an attractive therapeutic target. Several compounds targeting PNPLA3 are now in clinical development. While initial trials have focused on metabolic dysfunction-associated SLD, the recognition that almost all individuals with excessive alcohol consumption have metabolic comorbidities provides an unprecedented opportunity to evaluate these genetically informed therapies in MetALD. In this review, we examine the role of PNPLA3 in ALD, focusing on gene-environment interactions and therapeutic implications in the context of the new disease classification framework.

Keywords: MetALD; cirrhosis; gene–environment interaction; hepatocellular carcinoma.

PubMed Disclaimer

References

    1. Z. M. Younossi, P. Golabi, J. M. Paik, A. Henry, C. Van Dongen, and L. Henry, “The Global Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review,” Hepatology 77 (2023): 1335–1347.
    1. M. E. Rinella, J. V. Lazarus, V. Ratziu, et al., “A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature,” Journal of Hepatology 79 (2023): 1542–1556.
    1. M. Israelsen, S. Francque, E. A. Tsochatzis, and A. Krag, “Steatotic Liver Disease,” Lancet 404 (2024): 1761–1778.
    1. N. Ganne‐Carrié and P. Nahon, “Hepatocellular Carcinoma in the Setting of Alcohol‐Related Liver Disease,” Journal of Hepatology 70 (2019): 284–293.
    1. S. Romeo, J. Kozlitina, C. Xing, et al., “Genetic Variation in PNPLA3 Confers Susceptibility to Nonalcoholic Fatty Liver Disease,” Nature Genetics 40 (2008): 1461–1465.

LinkOut - more resources